HKEX: 2511
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
View original source (HKEXnews)
Earlier from Hightide Therapeutics
- 2026 Interim Report
- HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate...